Effect of once‐weekly semaglutide versus thrice‐daily insulin aspart, both as add‐on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open‐label, multinational, phase 3b trial

AIM: To compare the efficacy and safety of once‐weekly (OW) semaglutide versus thrice‐daily (TID) insulin aspart (IAsp) in participants with inadequately controlled type 2 diabetes (T2D) treated with insulin glargine (IGlar) and metformin. MATERIALS AND METHODS: SUSTAIN 11 (NCT03689374) was a random...

Descripción completa

Detalles Bibliográficos
Autores principales: Kellerer, Monika, Kaltoft, Margit Staum, Lawson, Jack, Nielsen, Lasse Lykke, Strojek, Krzysztof, Tabak, Ömür, Jacob, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545869/
https://www.ncbi.nlm.nih.gov/pubmed/35546450
http://dx.doi.org/10.1111/dom.14765

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545869/
https://www.ncbi.nlm.nih.gov/pubmed/35546450
http://dx.doi.org/10.1111/dom.14765

Ejemplares similares